Cargando…
Advances of adeno-associated virus applied in gene therapy to hemophilia from bench work to the clinical use
Hemophilia A and B are diseases caused by a single gene deficiency and are thus suitable for gene therapy. In recent clinical research, adeno-associated virus (AAV) was employed by several teams in the treatment of hemophilia A and B, and the outcomes were encouraging. In this review, we summarized...
Autores principales: | Pei, Xiaolei, Han, Mingzhe, Zhang, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975051/ https://www.ncbi.nlm.nih.gov/pubmed/35402808 http://dx.doi.org/10.1097/BS9.0000000000000030 |
Ejemplares similares
-
Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021) -
Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus
por: Puetz, John
Publicado: (2023) -
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
por: Fong, Sylvia, et al.
Publicado: (2022) -
Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
por: Sun, Junjiang, et al.
Publicado: (2022) -
Recent Advances in Hemophilia Gene Therapy
por: Karimipoor, Morteza
Publicado: (2019)